Targeting signal transduction pathways for the treatment of Kaposi sarcoma

Janet L. Douglas, Henry B. Koon, Ashlee V. Moses

Research output: Chapter in Book/Report/Conference proceedingChapter


Kaposi sarcoma (KS) is a multi-focal angioproliferative disease driven by infection of cells by Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV8). KSHV/HHV8 infection activates numerous sequential and parallel signaling pathways creating an angiogenic-inflammatory state that leads to the development of Kaposi sarcoma. These pathways can be grouped into KSHV/HHV8-specific pathways and cellular growth/angiogenic pathways that are pirated by KSHV/HHV8. Advances in our understanding of the pathogenesis of KS parallel the clinical development of signal transduction inhibitors. This chapter reviews the signaling pathways active in KSHV/HHV8-infected cells and discusses the use of clinical inhibitors of these pathways in the treatment of KS.

Original languageEnglish (US)
Title of host publicationMolecular Basis for Therapy of AIDS-Defining Cancers
PublisherSpringer New York
Number of pages15
ISBN (Print)9781441915122
StatePublished - 2010

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Targeting signal transduction pathways for the treatment of Kaposi sarcoma'. Together they form a unique fingerprint.

Cite this